Literature DB >> 10883669

The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo.

H T Zhang1, P A Scott, L Morbidelli, S Peak, J Moore, H Turley, A L Harris, M Ziche, R Bicknell.   

Abstract

Vascular endothelial growth factor (VEGF) is known to occur as at least six differentially spliced variants, giving rise to mature isoforms containing 121, 145, 165, 183, 189 and 206 amino acids. However, little is yet known concerning the in vivo activities of this differential splicing. Stably transfected MCF-7 breast carcinoma cells were constructed that secreted comparable amounts of the 121, 165 or 189 isoforms. Rabbit corneal angiogenesis assays showed the VEGF121 transfectant to have much greater angiogenic activity than the 165 or 189 expressing MCF-7 cells. While the VEGF121-expressing MCF-7 cells were reproducibly more tumorigenic than the control transfectants, this was not the case with the VEGF165- or VEGF189-expressing cells. More surprising was the observation that VEGF189 located to the nucleus, consistent with the presence of a highly conserved nuclear localization sequence in exon 6a that is expressed in VEGF189 but not 121 or 165. It was concluded that the VEGF121 isoform is both more angiogenic and tumorigenic than are the 165 and 189 isoforms. This is probably due to the ability of the 121 isoform, unlike the 165 and 189 isoforms, to freely diffuse from the cells producing it.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10883669      PMCID: PMC2374542          DOI: 10.1054/bjoc.2000.1279

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188.

Authors:  P Carmeliet; Y S Ng; D Nuyens; G Theilmeier; K Brusselmans; I Cornelissen; E Ehler; V V Kakkar; I Stalmans; V Mattot; J C Perriard; M Dewerchin; W Flameng; A Nagy; F Lupu; L Moons; D Collen; P A D'Amore; D T Shima
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Two interdependent basic domains in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence.

Authors:  J Robbins; S M Dilworth; R A Laskey; C Dingwall
Journal:  Cell       Date:  1991-02-08       Impact factor: 41.582

3.  Tumor growth and neovascularization: an experimental model using the rabbit cornea.

Authors:  M A Gimbrone; R S Cotran; S B Leapman; J Folkman
Journal:  J Natl Cancer Inst       Date:  1974-02       Impact factor: 13.506

4.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.

Authors:  E Tischer; R Mitchell; T Hartman; M Silva; D Gospodarowicz; J C Fiddes; J A Abraham
Journal:  J Biol Chem       Date:  1991-06-25       Impact factor: 5.157

5.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

Authors:  J E Park; G A Keller; N Ferrara
Journal:  Mol Biol Cell       Date:  1993-12       Impact factor: 4.138

6.  Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.

Authors:  K Smith; S Houlbrook; M Greenall; J Carmichael; A L Harris
Journal:  Oncogene       Date:  1993-04       Impact factor: 9.867

7.  Nuclear accumulation of interferon gamma.

Authors:  T Bader; J Weitzerbin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

8.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

Authors:  K A Houck; N Ferrara; J Winer; G Cachianes; B Li; D W Leung
Journal:  Mol Endocrinol       Date:  1991-12

9.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms.

Authors:  K A Houck; D W Leung; A M Rowland; J Winer; N Ferrara
Journal:  J Biol Chem       Date:  1992-12-25       Impact factor: 5.157

10.  Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P.

Authors:  M Ziche; L Morbidelli; E Masini; S Amerini; H J Granger; C A Maggi; P Geppetti; F Ledda
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

View more
  49 in total

1.  Evaluation of the angiogenesis inhibitor KR-31831 in SKOV-3 tumor-bearing mice using (64)Cu-DOTA-VEGF(121) and microPET.

Authors:  Iljung Lee; Kwang Yup Yoon; Choong Mo Kang; Xin Lin; Xiaoyuan Chen; Jung Young Kim; Sung-Min Kim; Eun Kyoung Ryu; Yearn Seong Choe
Journal:  Nucl Med Biol       Date:  2012-03-09       Impact factor: 2.408

Review 2.  Vascular endothelial growth factor biology: clinical implications for ocular treatments.

Authors:  R B Bhisitkul
Journal:  Br J Ophthalmol       Date:  2006-12       Impact factor: 4.638

3.  In vivo characterization of 68Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models.

Authors:  Choong Mo Kang; Sung-Min Kim; Hyun-Jung Koo; Min Su Yim; Kyung-Han Lee; Eun Kyoung Ryu; Yearn Seong Choe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-25       Impact factor: 9.236

4.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006

5.  Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.

Authors:  Selene Nunez-Cruz; Phyllis A Gimotty; Matthew W Guerra; Denise C Connolly; You-Qiang Wu; Robert A DeAngelis; John D Lambris; George Coukos; Nathalie Scholler
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

6.  The importance of -460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer.

Authors:  Torben F Hansen; Karen-Lise G Spindler; Karen A Lorentzen; Dorte A Olsen; Rikke F Andersen; Jan Lindebjerg; Ivan Brandslund; Anders Jakobsen
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-11       Impact factor: 4.553

7.  High expression of a novel splicing variant of VEGF, L-VEGF144 in glioblastoma multiforme is associated with a poorer prognosis in bevacizumab treatment.

Authors:  Wen-Yu Cheng; Chiung-Chyi Shen; Ming-Tsang Chiao; Yea-Jiuan Liang; Tsuo-Fei Mao; Bai-Shuan Liu; Jun-Peng Chen
Journal:  J Neurooncol       Date:  2018-06-16       Impact factor: 4.130

Review 8.  Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland.

Authors:  Carmen Clapp; Stéphanie Thebault; Gonzalo Martínez de la Escalera
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

9.  Expression of VEGF121 and VEGF165 in hypertrophic chondrocytes of the human growth plate and epiphyseal cartilage.

Authors:  Wolf Petersen; Michael Tsokos; Thomas Pufe
Journal:  J Anat       Date:  2002-08       Impact factor: 2.610

10.  Functional significance of vascular endothelial growth factor receptor expression on human glioma cells.

Authors:  Rolf Mentlein; Frauke Forstreuter; Hubertus M Mehdorn; Janka Held-Feindt
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.